NCT04209049View on ClinicalTrials.gov

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

PHASE1CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

January 5, 2021

Study Completion Date

January 5, 2021

Conditions

OverweightObesity

Interventions

DRUG

NNC0174-0833

A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.

Trial Locations (2)

32806

Novo Nordisk Investigational Site, Orlando

33136

Novo Nordisk Investigational Site, Miami

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY